NYSE · LLY
Eli Lilly and Company
$1,373.00+$84.70 (+6.57%)
Eli Lilly and Company’s quoted price sits in the upper half of its reported 52-week range, 2.51% below the high.
Loading market information…
NASDAQ · NRC · USD
Stock price, dividends, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
NRC Health’s quoted price sits in the upper half of its reported 52-week range, 3.73% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
NRC Health’s forward annual dividend is $0.64 per share, paid quarterly. The forward yield is 2.72% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
NRC Health’s next earnings report is currently expected on Feb 2, 2027, with estimated earnings per share of $0.25. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow NRC Health’s reporting calendar.
THE COMPANY BEHIND THE TICKER
National Research Corporation (NRC) empowers healthcare organizations across the United States and Canada with data-driven analytics and actionable insights to enhance both patient and employee experiences. Through a comprehensive suite of subscription-based solutions, NRC supplies crucial information and analysis, addressing vital aspects such as the overall patient journey, service recovery initiatives, effective transitions of care, health risk assessments, fostering employee engagement, and enhancing reputation management and brand loyalty. Beyond these, NRC provides market intelligence to help organizations understand brand awareness, public perception, and competitive positioning. They offer advanced segmentation tools to analyze community needs, wants, and behaviors in real-time. Specialized health risk assessment tools are available to help clients pinpoint and support high-risk populations, fostering preventative care strategies and wellness initiatives. Similarly, transition management solutions assist in identifying and managing at-risk patients during care changes, aiming to reduce readmissions and ensure smooth, satisfactory transitions. NRC also offers transparency tools, empowering healthcare providers to present clear organizational information to consumers, thereby supporting informed decision-making. Furthermore, governance solutions are tailored for the leadership of non-profit hospitals and health systems, including boards of directors, executives, and physician leaders. Their clientele includes integrated health systems, post-acute care providers, and healthcare payer organizations. Established in 1981, National Research Corporation maintains its headquarters in Lincoln, Nebraska.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 01:03 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
| Feb 11, 2025 |
| $0.36 |
| $36.91M |
KEEP COMPARING
$1,373.00+$84.70 (+6.57%)
Eli Lilly and Company’s quoted price sits in the upper half of its reported 52-week range, 2.51% below the high.
$33.80+$0.07 (+0.21%)
HealthStream, Inc.’s quoted price sits in the upper half of its reported 52-week range, 5.08% below the high.
$12.53+$0.16 (+1.29%)
Phreesia, Inc.’s quoted price sits in the lower half of its reported 52-week range, 47.31% below the high.
$7.97+$0.10 (+1.27%)
SOPHiA GENETICS S.A.’s quoted price sits in the upper half of its reported 52-week range, 11.25% below the high.
$24.00+$1.00 (+4.35%)
Claritev Corporation’s quoted price sits in the lower half of its reported 52-week range, 67.43% below the high.
$1.79-$0.01 (-0.56%)
Health Catalyst, Inc.’s quoted price sits in the lower half of its reported 52-week range, 46.88% below the high.
$1.12-$0.02 (-1.75%)
Definitive Healthcare Corp.’s quoted price sits in the lower half of its reported 52-week range, 62.67% below the high.
$1.80+$0.03 (+1.69%)
CareCloud, Inc.’s quoted price sits in the lower half of its reported 52-week range, 52.76% below the high.
THE ANALYST VIEW
1 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
